Our portfolio

CEPI is providing US$850,000 for the development of 20Med's bioresponsive polymeric nanoparticle technology, which could help end the need for frozen storage of mRNA vaccines. This funding will be used to advance a proof-of-concept for 20Med's nanoparticle platform, as well as for preclinical studies to assess whether the technology can deliver mRNA vaccines as effectively as the currently approved technology used for mRNA delivery, known as lipid nanoparticles.

CEPI is providing up to US$2.87 million to ACM Biolabs for preclinical proof of concept of its mRNA delivery technology—the ACM Tunable Platform (“ATP”). ATP is a thermostable mRNA delivery vehicle that allows for mRNA storage at 2-8°C, in contrast to most existing mRNA delivery systems, which require ultra-low temperatures for storage.

The project will use Rabies as a model pathogen.

CEPI is providing up to US$1.6 million to establish proof-of-concept for aVaxziPen's vaccine-delivery technology by evaluating stability, delivery and preclinical immunogenicity of both mRNA and protein-based vaccines developed using aVaxziPen's platform.

aVaxziPen's solid-dose vaccine technology uses a pen applicator device and is designed to address access challenges associated with cold-chain storage requirements by protecting the mRNA and proteins against degradation, potentially removing the need for frozen storage for mRNA vaccines and the need for cold-chain storage altogether for protein-based vaccines.

CEPI is providing up to US$1.45 Million to investigate the role of bacterial outer membrane vesicles (OMVs) in boosting a special type of protection—known as mucosal immunity—which scientists believe could be key to stopping the onward transmission of viruses. Abera Bioscience researchers will use the CEPI funding to decorate OMVs, developed on its proprietary vaccine platform, BERA, with antigens produced by cell-free-production methods, resulting in new immune-boosted nasal vaccine sprays and powders. The BERA platform enables decoration of OMVs with antigens into one particle, by contrast with existing OMV vaccines consisting of a mix of OMVs and antigens. In this project, flu vaccines will be tested for proof-of-concept in preclinical models and the level of immunogenicity induced during the testing will be benchmarked against currently approved flu vaccines.

CEPI is providing up to US$12.4 Million with support from EU’s Horizon Europe programme to develop a broadly protective vaccine against several filoviruses including Ebolavirus Zaire, Sudan Ebolavirus and Marburg. AdaptVac will lead a global consortium building on AdaptVac’s innovative Virus-Like-Particle vaccine platform to create several different vaccine constructs which will be tested in preclinical studies. The most promising vaccine candidate will progress into Phase 1/2 clinical trials.